欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (12): 1412-1415.

• 研究原著 • 上一篇    下一篇

国产头孢丙烯颗粒剂人体药代动力学和生物等效性研究

苏梦翔, 狄斌1, 于锋, 沈建平2, 张银娣2   

  1. 中国药科大学药理研究室,1药物分析教研室, 南京 210009, 江苏;
    2南京医科大学临床药理学研究所, 南京 210029, 江苏
  • 收稿日期:2005-10-27 修回日期:2005-12-08 出版日期:2005-12-26 发布日期:2020-11-11
  • 作者简介:苏梦翔,男,在读硕士研究生,从事临床药代动力学研究。Tel:(0)13851993220E-mail:sumx2000@sohu.com

Study of pharmacokinetics and bioequivalence about cefprozil granules in healthy volunteers

SU Meng-xiang, DI Bin1, YU Feng, SHENG Jian-ping2, ZHANG Yin-di2   

  1. Research Department of Pharmacology,China Pharmaceutical University,Nanjing 210009,Jiangsu,China;
    1Department of Pharmaceutical Analysis,China Pharmaceutical University,Nanjing 210009,Jiangsu,China;
    2Clinical harmacology Institute,Nanjing Medical University,Nanjing 210029,Jiangsu,China
  • Received:2005-10-27 Revised:2005-12-08 Online:2005-12-26 Published:2020-11-11

摘要: 目的: 建立HPLC-UV 法同时测定人血浆中的顺式和反式头孢丙烯,对国产头孢丙烯颗粒剂和胶囊剂进行人体药代动力学研究和人体相对生物等效性研究。方法: 将20 名健康志愿者分两组进行单剂量双交叉试验,剂量均为500 mg,两次试验间隔时间为7d 。血浆样品用20 %的三氯醋酸沉淀蛋白后,用乙腈和二氯甲烷的混合溶剂提取内源性杂质,离心后取上清液进样分析;色谱柱为LichrospherC8 柱(5μm,4.6 mm×30 cm),流动相为乙腈-1.5 %的乙酸水溶液(15∶85),流速:1.0 ml·min-1,检测波长:280 nm,柱温为30 ℃,内标为头孢拉定。结果: 血浆中杂质不干扰样品的测定,标准曲线范围为0.0209~ 10.47 mg·L-1,线性关系良好(r=0.9993),最低定量限为0.0209 mg·L-1;参比制剂与受试制剂的达峰时间分别为1.7±0.3 h,1.8±0.2 h;达峰浓度分别为:4.45±1.25 mg·L-1 、4.88±1.08 mg·L-1,生物半衰期分别为1.89±0.45 h 和1.79±0.39 h,用梯形法计算所得的AUC0-12 分别为:12.11±2.62mg·L-1·h-1 、12.34±2.93 mg·L-1·h-1,头孢丙烯受试制剂的相对生物利用度为:(101.9±8.8)%。结论: 本分析方法操作简便,结果准确可靠。对Cmax 、AUC0-12经对数转换,方差分析后进行双单侧检验及90 %可信限判断,两制剂具有生物等效性。

关键词: 头孢丙烯, 药代动力学, 生物等效性, HPLC, 颗粒剂

Abstract: AIM: Use the HPLC-UV method to determine the contents of cis-cefprozil and trans-cefprozil in human plasma in orderto evaluate the pharmacokinetics and bioequivalence of cefprozil granules (testing granules and reference tablets) in healthy volunteers.METHODS: 20 healthy volunteers were classified into two groups forsingle dose and two-crossing test,with the dose of 500 mg,10 volunteers each grouPand seven days interval between two tests.Afterthe plasma protein was precipitated by 20 % trichloroacetic acid,endogenesis impurities in plasma was extracted with the mixtuerof acetonitrile and dichloromethane,then the supernatant was analyzed by HPLC.LichrospherC8 column(5μm,4.6 mm×30 cm)was applied,using acetonitrile-1.5 % acetic acid watersolution (15∶85,v/v)as mobile phase with the flow rate of 1.0 ml·min-1.The detection wavelength was 280 nm and column temperature was 30 ℃,the internal standard was cefradine.RESULTS: Endogenous materies didn' t disturb the determination of cefprozil.Within the range of 0.0209-10.47μg·ml-1,peak area and injection quantity were in linearcorrelation (r=0.9993).The limit of quantification was 0.0209 mg·L-1.The main pharmacokinetic parameters Tmax,Cmax and t1/2 were 1.7±0.3 h,4.45±1.25 mg·L-1,1.89±0.45 h forthe reference tablets;1.8±0.2 h,4.88±1.08 mg·L-11.79±0.39 h forthe test granules respectively.AUC0-12were 12.11±2.62,12.34±2.93 mg·L-1·h-1 and the relative bioavailability was (101.9±8.8)%.CONCLUSION: The method is simple,accurate and reliable.There is no significant difference between the two formulations in the Cmax,and AUC0-12.The two formulations are bioequivalence.

Key words: cefprozil, pharmacokinetics, bioequivalence, HPLC, granules

中图分类号: